Curis, Inc. (CRIS) Stock Rating Lowered by ValuEngine
Curis, Inc. (NASDAQ:CRIS) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.
CRIS has been the topic of several other reports. Zacks Investment Research raised Curis from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. BidaskClub raised Curis from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 17th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. Curis presently has an average rating of “Hold” and a consensus price target of $5.50.
Shares of Curis (NASDAQ CRIS) opened at 1.72 on Friday. Curis has a 1-year low of $1.47 and a 1-year high of $3.72. The firm’s market cap is $247.47 million. The company’s 50 day moving average price is $1.82 and its 200-day moving average price is $2.13.
Curis (NASDAQ:CRIS) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The company had revenue of $2.10 million for the quarter, compared to analyst estimates of $2.08 million. Curis had a negative return on equity of 236.43% and a negative net margin of 836.18%. The firm’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same period last year, the firm earned ($0.09) earnings per share. Equities analysts expect that Curis will post ($0.40) EPS for the current fiscal year.
WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/17/curis-inc-cris-stock-rating-lowered-by-valuengine.html.
A number of hedge funds and other institutional investors have recently modified their holdings of CRIS. Point72 Asset Management L.P. purchased a new position in Curis in the first quarter valued at about $1,391,000. Perceptive Advisors LLC purchased a new position in Curis in the first quarter valued at about $1,390,000. FMR LLC grew its stake in Curis by 2.7% in the first quarter. FMR LLC now owns 15,131,961 shares of the biotechnology company’s stock valued at $42,067,000 after purchasing an additional 393,582 shares in the last quarter. Vanguard Group Inc. grew its stake in Curis by 6.7% in the first quarter. Vanguard Group Inc. now owns 4,827,625 shares of the biotechnology company’s stock valued at $13,421,000 after purchasing an additional 304,268 shares in the last quarter. Finally, State Street Corp grew its stake in Curis by 10.4% in the second quarter. State Street Corp now owns 1,857,044 shares of the biotechnology company’s stock valued at $3,511,000 after purchasing an additional 175,424 shares in the last quarter. Hedge funds and other institutional investors own 50.94% of the company’s stock.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Stock Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related stocks with our FREE daily email newsletter.